Results 91 to 100 of about 31,541 (206)

Lopinavir/Ritonavir: A Review for 2011 [PDF]

, 2011
Ritonavir-boosted lopinavir (LPV/r) is a boosted protease inhibitor (PI) combination used as an alternative agent in the management of the human immunodeficiency virus (HIV).
Mark Goodman, Robyn Teply, Christopher J. Destache   +2 more
core   +1 more source

KSHV Genome in Saliva, Whole Blood and Kaposi's Sarcoma Biopsy Specimens in Republic of Congo: Phylogenetic Analysis and an APOBEC3B Mutational Signature

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Kaposi's sarcoma‐associated herpesvirus (KSHV) has been associated with a variety of diseases and is endemic in Sub‐Saharan Africa. We performed KSHV‐whole‐genome analysis and search for APOBEC‐editing to describe genetic diversity in samples issued from an endemic region.
Gervillien Arnold Malonga, Valentin Leducq, Antoine Fauchois, Dimitry Moudiongui Mboungou Malanda, Patrina Joseph Iloukou Mayakia, Juthèce Private Malanda‐Kiminou, Ferdinand Emaniel Brel Got, Fabien Gaël Mouamba, Vincent Calvez, Jean Felix Peko, Anne‑Geneviève Marcelin, Aude Jary   +11 more
wiley   +1 more source

Pharmacogenomics landscape of COVID-19 therapy response in Serbian population and comparison with worldwide populations [PDF]

Journal of Medical Biochemistry, 2020
Background: Since there are no certified therapeutics to treat COVID-19 patients, drug repurposing became important. With lack of time to test individual pharmacogenomics markers, population pharmacogenomics could be helpful in predicting a higher risk ...
Stanković Biljana, Kotur Nikola, Gašić Vladimir, Klaassen Kristel, Ristivojević Bojan, Stojiljković Maja, Pavlović Sonja, Zukić Branka   +7 more
doaj  

Associations of SLCO1B1 polymorphism with virological efficacy in children with HIV infection

Сибирский научный медицинский журнал
The aim of the study was to identify the association between polymorphism of the SLCO1B1 gene and virological efficacy in children receiving lopinavir as part of their antiretroviral therapy.Material and methods.
A. Yu. Sambyalova, T. A. Bairova, T. L. Eletskaya, A. V. Belskikh, E. V. Belyaeva, O. A. Ershova, N. V. Nemchinova, V. V. Sinkov, Yu. K. Plotnikova, L. V. Rychkova   +9 more
doaj   +1 more source

Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy [PDF]

, 2012
Objectives: To evaluate the pharmacokinetic profile of ritonavir-boosted lopinavir in HIV-infected patients during rifabutin-based anti-mycobacterial therapy.
Matteelli A., Carvalho A. C. C., Marcantoni C., Calabresi A., Dal zoppo S., Villani P., Apostoli A., Regazzi M., El-Hamad I., Bigoni S., Cusato M.   +10 more
core   +1 more source

Population Pharmacokinetics of Lopinavir and Ritonavir in Combination with Rifampicin-Based Antitubercular Treatment in HIV-Infected Children [PDF]

, 2012
Background The preferred antiretroviral regimen for young children previously exposed to non-nucleoside reverse transcriptase inhibitors is lopinavir/ ritonavir plus two nucleoside reverse transcriptase inhibitors.
Simonsson, Ulrika S. H.,, Yuan Ren, McIlleron, Helen, Jan-Stefan van der Walt, Mats O Karlsson, Ren, Yuan, Paolo Denti, Karlsson, Mats O,, Denti, Paolo, Chao Zhang, Helen McIlleron, Zhang, Chao, Ulrika SH Simonsson, van der Walt, Jan-Stefan,   +13 more
core   +1 more source

Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice daily. [PDF]

, 2012
Item does not contain fulltextWe assessed pharmacokinetic (PK) parameters of reduced dose lopinavir/ritonavir (LPV/r) and compared generic and branded tablets. Twenty HIV-infected patients using protease inhibitors with HIV RNA
Burger, David M., Gorowara, Meena, Avihingsanon, A., Lange, J.M.A., Ananworanich, J., Chuleeporn Khongpetch, Burger, D.M., Praphan Phanuphak, Joep M. A. Lange, Jiratchaya Wongsabut, van der Lugt, Jasper, Wongsabut, J., Gorowara, M., Reshmie A. Ramautarsing, Lugt, J. van der, Phanuphak, P., Avihingsanon, Anchalee, Ruxrungtham, Kiat, Lange, Joep M. A., Kiat Ruxrungtham, Ramautarsing, R.A., Wongsabut, Jiratchaya, Anchalee Avihingsanon, Phanuphak, Praphan, Ramautarsing, Reshmie A., Jintanat Ananworanich, David M. Burger, Ananworanich, Jintanat, Meena Gorowara, Ruxrungtham, K., Khongpetch, C., Jasper van der Lugt, Khongpetch, Chuleeporn   +32 more
core   +1 more source

Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. [PDF]

, 2006
Contains fulltext : 50676.pdf (Publisher’s version ) (Open Access)BACKGROUND: Limited data are available about the effect of lopinavir and low-dose ritonavir on glucuronidation. Lamotrigine undergoes glucuronidation.
Burger, D.M., Hofstede, H.J.M. ter, Caliskan-Yassen, N., Lee, M.J. van der, Graaff, M.J.A. de, Ewijk-Beneken Kolmer, E.W.J. van, Koopmans †, P.P., Dawood, L.   +7 more
core   +1 more source

Analysis of some antiretroviral drugs in bulk, pharmaceutical formulations and biological fluid [PDF]

, 2012
Not ...
Mardia, Rajnikant B.
core  

Freeze-Dried Lopinavir-Loaded Nanostructured Lipid Carriers for Enhanced Cellular Uptake and Bioavailability: Statistical Optimization, in Vitro and in Vivo Evaluations

Pharmaceutics, 2019
Nanostructured lipid carriers (NLCs) loaded with lopinavir (LPV) were prepared by the high-shear homogenization method. The LPV-NLCs formulations were freeze-dried using trehalose as a cryoprotectant.
Arshad Ali Khan, Jahanzeb Mudassir, Safia Akhtar, Vikneswaran Murugaiyah, Yusrida Darwis   +4 more
doaj   +1 more source